Intra-cellular Therapies Stock News

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades For United Airlines Holdings Inc (NASDAQ:UAL), Argus Research upgraded the previous rating of Hold to Buy. For the first quarter, United Airlines Holdings had an EPS of $4.24, compared to yea

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2

Wasatch Global Investors, an investment management firm, published its “Wasatch Small Cap Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.

CAPLYTA has been approved by the FDA for the treatment of adults with schizophrenia and adults with bipolar depression.

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ: ITCI ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for Intra-Cellular Therapies. The company has an average price target of $59.67 with a high of $65.00 and a low of $50.00. Below is a summary of how these 6 analysts rated Intra-Cellular Therapies over the past 3 months. … Full story available on Benzinga.com

Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q4 2021 Results - Earnings Call Transcript

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

Intra-Cellular Therapies press release (NASDAQ:ITCI): Q4 GAAP EPS of -$1.05 misses by $0.05.Revenue of $25.67M (+106.2% Y/Y) beats by $0.74M.

Received FDA approval for CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults.